Texas sued the drug maker for defrauding the state’s Medicaid program by promoting risperidone for uses not approved by the FDA. The Texas Risperdal Lawsuit was settled in 2012, for $158 million. In order to boost sales of their new drug, plaintiffs allege the company embarked upon an aggressive off-label marketing campaign to market Risperdal for agitated elderly patients in nursing homes, behavioral disturbances and conduct disorders in children, attention deficit disorder, and other mood and anxiety symptoms unrelated to any psychotic disorder. The lawsuits contain a variety of allegations including the drugmaker's concealment of Risperdal's harmful side effects such as the development of gynecomastia in young men. The selected documents in this collection concern Janssen Pharmaceuticals and Johnson & Johnson, the maker of Risperdal (risperidone), a medication used to treat schizophrenia. Janssen, Ortho-McNeil, and Johnson & Johnson, Inc, et al. Johnson & Johnson Company, Janssen Pharmaceutical Products, et al. Andrew Bentley, minor, by Jennie Rolen vs Janssen Pharmaceuticals, Inc., Johnson & Johnson and Janssen Research & Development, LLC, Exerpta Medica and Elsevier, Inc.Allen Jones v Janssen Pharmaceutical Products, LP, Janssen Pharmaceutica, Inc., Johnson & Johnson, Inc.

Janssen Pharmaceuticals, Johnson & Johnson Company and Janssen Pharmaceutical Research and Development, LLC Camille McGowan and Judy Doetterl v Janssen Pharmaceutical Products, LP, Janssen Pharmaceutica, Inc., Johnson & Johnson, Inc. The selected documents in this collection come from journalist Steven Brill's own research as well as the following lawsuits:

Risperdal recent news